Hospital PMI® at 56%; February 2025 Hospital ISM® Report On Business®
TEMPE, Ariz., March 7, 2025 /PRNewswire/ -- Economic activity in the hospital subsector grew in February for the 18th consecutive month...
COVID-19
COEPTIS’ NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan
Leveraging Advanced AI and Robotics to Revolutionize Marketing Strategies in Defense and Security SectorsWEXFORD, Pa., March 07, 2025 (GLOBE NEWSWIRE)...
HyBryte™ Treatment Studies Presented at Two Medical Conferences in March
Two Presentations Highlight Data Demonstrating Hypericin Photodynamic Therapy Potential with a Preliminary Comparison to Current Therapy PRINCETON, N.J., March 6,...
Hemostemix and FireFly Neuroscience’s Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01
A growing body of clinical evidence supports the use of Firefly's FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment...
Hemostemix Sells Its 23rd ACP-01 Therapy Convertible Debenture
Calgary, Alberta--(Newsfile Corp. - March 5, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous...
Medical Refrigerators Market Size Set for Tremendous Growth, Projected to Reach US$ 6.49 Billion by 2028, Growing at 5.8% CAGR, Says The Insight Partners
NEW YORK, March 4, 2025 /PRNewswire/ -- According to a comprehensive report from The Insight Partners, "Medical Refrigerators Market Size and...
MyClearStep and Teamworks Shake Up Athlete Performance Tech–A Seamless Integration That’s Changing the Game
CUPERTINO, Calif., March 4, 2025 /PRNewswire/ -- Say goodbye to outdated weigh-ins and hello to precision, efficiency, and next-level insights. MyClearStep,...
VIVUS Unveils Global Initiative to Advance Healthy and Sustainable Weight Management
VIVUS reaffirms commitment to combatting global obesity crisis on World Obesity Day 2025 with VIVUS For Life CAMPBELL, Calif., March...
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention
BERKELEY, Calif. and MAINZ, Germany, March 03, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),...
Oryzon Defines Phase III Trial Endpoints for Agitation and Aggression in BPD with Input From New Clinical Advisory Board
Leading US psychiatric experts join Oryzon’s Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality...
InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today...
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains Paul Goepfert, MD, Director for the...
Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company’s Continuous Glucose Monitoring Technology
DUBLIN, Ireland, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human...
Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
TARRYTOWN, N.Y., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency’s...
Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule
NEWTOWN, Pa., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW) (“Traws” or “Traws Pharma”), a clinical stage...
NEJM AI Study Reveals 84% Faster Resolution of Patient Messages with Clinician-Trained NLP Model
ATLANTA, Feb. 27, 2025 /PRNewswire/ -- A new study published in the New England Journal of Medicine reveals that clinician-trained AI...
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director
David Chemerow David Chemerow OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the...
IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to...
Groundbreaking Health Podcast “Docology” Launching March 18th
Global Health Leader Howard Zucker Teams With HANG Media to Invite the Audience Onto The Show NEW YORK, Feb....
AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
Several subjects who received the highest dose in Phase 1 will also be included in Phase 2OCALA, Fla., Feb. 25,...